Uncategorized

Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs Full Release available here

Read the full article from the University of Wisconsin – Madison here. A series of projects aimed at advancing the human-health and economic impact of biomanufacturing is already benefiting from a new University of Wisconsin–Madison institute aimed at making the state a Midwestern hub of the ongoing merger of pharmaceuticals, medical devices and cutting-edge tissue […]

For Immediate Release August 17, 2016 Winners Announced for 2016 Wisconsin Innovation Awards Ten Winners Announced at Madison Awards Ceremony Milwaukee— August 17, 2016 — Ten winners have been announced from the thirtyfive finalists and more than 180 nominees for the 2016 Wisconsin Innovation Awards. At an awards ceremony emceed by Jeanan Yasiri Moe and […]

MADISON, Wis., June 15, 2016 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Preventive Services Task Force (USPSTF) issued its final 2016 colorectal cancer screening recommendations and clarified the inclusion of Cologuard® (FIT-DNA) on equal standing among the other included screening tests. “We believe the final recommendations provide an important level […]